For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 8,083 | 6,553 | ||
| General and administrative | 3,281 | 3,342 | ||
| Goodwill impairment charge | 0 | 0 | ||
| Fair value adjustment for contingent consideration | 2,066 | 532 | ||
| Total operating expenses | 13,430 | 10,427 | ||
| Loss from operations | -13,430 | -10,427 | ||
| Fair value adjustment for debt | 549 | - | ||
| Fair value adjustment for warrants | -291 | 4,464 | ||
| Warrant issuance costs | 42 | 872 | ||
| Interest income | 300 | 311 | ||
| Fair value adjustment for long-term debt | - | 501 | ||
| Other income (expense), net | -58 | -29 | ||
| Net loss before income tax expense | -13,488 | -15,982 | ||
| Income tax benefit (expense) | -46 | 67 | ||
| Net loss | -13,442 | -16,049 | ||
| Foreign currency translation adjustments | 125 | 4,216 | ||
| Unrealized gain (loss) on available-for-sale securities | 12 | -17 | ||
| Total comprehensive loss | -13,305 | -11,850 | ||
| Basic EPS | -0.25 | -0.34 | ||
| Diluted EPS | -0.25 | -0.34 | ||
| Basic Average Shares | 53,951,371 | 46,686,239 | ||
| Diluted Average Shares | 53,951,371 | 46,686,239 | ||
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)